KOL Insight

Datamonitor Healthcare Type 2 Diabetes KOL Interview – Italy

In this interview with an Italian KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

Datamonitor Healthcare Multiple Myeloma KOL Interview – UK

This interview covers the current treatment of multiple myeloma in the UK, and the main areas of unmet need.

Aromatase Resistance and Palbociclib for Breast Cancer

These pathways can be targeted either at the cell surface receptor

level or their downstream signaling cascades. Currently, everolimus in combination with

exemestane represents a new standard of care for patients progressing on non-steroidal AIs.

HDAC inhibitors have also shown promising results For innate resistance, the combination of

fulvestrant and AI in the front line setting represents a new treatment option, particularly for

patients who present with de novo metastatic disease.

Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – US

An interview with a US key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine

Datamonitor Healthcare Systemic Lupus Erythematosus KOL Interviews

Datamonitor Healthcare interviewed two experts on systemic lupus erythematosus (SLE) based in the US to gauge their views on currently available treatment options, pipeline drugs and challenges with clinical trial design in SLE.